Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455403 · ClinicalTrials.gov registry record · NA
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 357
- Enrollment target
NCT00455403 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 357 participants.
The verdict
NCT00455403, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 357 participants
- Enrollment target
Study Summary
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the long-term effectiveness of chloroquine, a protein-activation medication, at reducing the progression of atherosclerosis in patients with the metabolic syndrome. Sub-study: Vascular endothelial growth factor(VEGF)and Cardiometabolic Risk, The purpose is to determine if the association of VEGF with atherosclerosis indicates that it should be a marker of the disorder.
Interventions
- DRUG Placebo Comparator
- DRUG Chloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455403
The ClinicalTrials.gov registry entry for NCT00455403 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT00455403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00455403 about?
NCT00455403 is a clinical study titled "Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)". Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the long-term effectiveness of chloroquine, a protein-activation medication, at reducing the progression of ...
What is the current status of trial NCT00455403?
This trial is currently completed. It is a NA study. The enrollment target is 357 participants. The study started on 2006-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00455403?
The interventions under investigation include: Placebo Comparator (DRUG), Chloroquine (DRUG).
Who is sponsoring clinical trial NCT00455403?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.